A COMPARATIVE STUDY ON THE THERAPEUTIC EFFICACY OF TOPICAL TOFACITINIB 2 PERCENT OINTMENT WITH EXCIMER LASER 308nm VERSUS TOPICAL TOFACITINIB 2 PERCENT OINTMENT MONOTHERAPY IN STABLE

A total of 52 patients with stable vitiligo fulfilling inclusion criteria will be

enrolled in our study.

Study design: Randomized comparative prospective study.

Place of study: Department of Dermatology, ERA’s Lucknow Medical College & Hospital, Lucknow, India.

Sample size: 52 patients (26 patients in each group)

Study period: 24 months

Method of sampling: Simple Random Sampling.

STUDY DESIGN: Randomized comparative prospective study.

Written informed consent will be taken from patients prior to participation inthe study.Patients will be randomly divided into two groups – A and B each containing 26 individuals.History and clinical examination with photographic documentation, VASI (Vitiligo Area Severity Index) score and subjective response before starting treatment and then at each visit (4, 8, 12 and 16 weeks).Follow-up visits at 4, 8, 12, 16, 20 and 24 weeks will be conducted and results will be tabulated in respective tables. In  one group  – Patient will be advised to apply topical tofacitinib (2%) ointment twice daily AND undergo excimer laser (308nm) therapy twice a week over the lesion for a duration of 12 weeks.

In another group  – Patient will be advised to apply topical tofacitinib (2%) ointment alone, twice daily over the lesion for a duration of 12 weeks.Patients will be assessed at baseline then followed up at 4, 8, 12 and 16

weeks and at each follow up visit clinical response will be determined by the reduction in VASI score and Subjective response. Based on the reduction in the VASI score and Subjective response the therapeutic efficacy is graded.

Assessment will be done at baseline , 0, 4 8 12, 16 weeks.